Objective: To investigate the influence of blockade of the renin-angiotensin system (RAS) on adipocytes, we compared the effect of telmisartan versus valsartan and amlodipine on adipocyte cellularity in the spontaneously type 2 diabetic, obese rat model.
R
ecent reports suggest that the angiotensin II (Ang II) receptor blockers (ARBs) losartan, 1 candesartan, 2 and valsartan 3 can suppress the new onset of diabetes mellitus and that the renin-angiotensin system (RAS) is implicated in the mechanism of onset of type 2 diabetes mellitus accompanied by hypertension. It is considered that Ang II inhibits the intracellular insulin-signaling pathway at the levels of IRS-1 and PI-3 kinase in the vascular smooth muscle cells. In addition, Ang II-induced increases in oxidative stress are considered to act antagonistically on the intracellular insulin-signaling pathway. In this context, ARBs, by blocking AT1 receptors, are considered to eliminate these effects of Ang II, thereby improving insulin resistance. 4, 5 It is also assumed that Ang II suppresses the differentiation of adipocytes as well as increases the number of enlarged adipocytes, 6, 7 whereas ARBs promote the differentiation and recruitment of preadipocytes, as well as increase the number of small, insulinsensitive adipocytes. 8 Suppression of this AT1 receptormediated action of Ang II that induces insulin resistance by directly blocking the receptors is considered to be a class effect of ARBs. In this regard, it is suggested that, unlike the other ARBs, telmisartan may also have PPAR-␥-mediated insulin-sensitizing properties. 9, 10 Moreover, Sugimoto et al 11 reported that telmisartan exerts greater effects on reducing adipocyte size than valsartan. In this study, we compared the effect of the PPAR-␥-activating ARB telmisartan versus the non-PPAR-␥-activating ARB valsartan and amlodipine on adipocyte cellularity in the spontaneously type 2 diabetic, obese rat model.
Methods

Animals
Male Otsuka Long Evans Tokushima Fatty (OLETF) rats, 12, 13 which are characterized by insulin resistance and accumulated intra-abdominal fat 15 and therefore available as a model for human metabolic syndrome, were obtained at 4 weeks of age from the Tokushima Research Institute, Otsuka Pharmaceutical (Tokushima, Japan). The animals were housed in plastic cages (320 by 270 by 175 mm) in an animal room at a controlled temperature (23°Ϯ 2°C) and a relative humidity (55% Ϯ 15%) and kept in a 12-h light/12-h dark cycle (lights on at 7 AM). They were supplied with rat chow (CE-2; Clea Japan, Tokyo, Japan) and tap water ad libitum until 8 weeks of age. The Guidelines for Laboratory Animal Facilities of the Jikei University School of Medicine were followed for the care and use of the animals in this study, and the protocol for the animal experiments in this study was approved by the institutional ethics committee.
Experimental Design
When the rats were 8 weeks old, they were randomly divided into four groups as follows: valsartan group (10 mg/kg, n ϭ 12), telmisartan group (5 mg/kg, n ϭ 12), amlodipine group (2 mg/kg, n ϭ 12), and control group (n ϭ 12). Each commercially available drug was mixed with chow and was given for 16 weeks. These doses of the drugs showed a similar antihypertensive effect on blood pressure (BP) in OLETF rats (Table 1) . Food intake and body weight were measured every week throughout the experimental period.
The 16-week-old rats (n ϭ 6 per group) were fasted for 17 h, after which they were subjected to an oral fat-loading test. The rats were given, orally, fat emulsion (Intralipos, Welfide, Osaka, Japan) at a dose of 10 mL/kg (containing 1 g of soybean oil). Samples of the peripheral blood were drawn from the retro-orbital sinus at regular intervals (0, 60, 120, 180 min after fat loading), and blood triglyceride (TG), free fatty acids (FFA), and lipoprotein fractions were measured. The area under the curve (AUC) was calculated for TG. Plasma glucose and insulin levels were also determined using the blood samples before fat loading.
At the end of the study, the weight of subcutaneous, retroperitoneal, and mesenteric adipose tissue, as well as that of adipose tissue around the epididymis and the liver was measured. The left lobe of the liver and the left paravertebral muscle of each rat were harvested for lipid extraction.
Blood Pressure Measurement
Each rat was warmed for 5 min with a preheated plate at 40°C and then moved to a cylindrical box for immobilization and heating. Blood pressure was measured at the age of 22 weeks in unanesthetized rats by a tail-cuff apparatus (BP-98A; Softron, Tokyo, Japan).
Biochemical Analysis
Blood samples were immediately centrifuged at 4°C, and the plasma was separated, which was then stored at Ϫ20°C until they were subjected to assay. Plasma glucose levels were determined by the glucose oxidase method using a commercial kit (Glucose C2; Wako Pure Chemical, Osaka, Japan). Plasma TG and free fatty acid (FFA) levels were measured enzymatically using enzyme reagents (Triglyceride E; Wako Pure Chemicals; NEFA-SS, Eiken Chemical, Tokyo, Japan). Plasma insulin levels were determined with commercial enzyme-linked immunoassay kits (Ultra Sensitive Rat Insulin Kit, Seikagaku, Tokyo, Japan). The plasma TG levels in lipoprotein fractions were determined by agarose gel electrophoresis, followed by TG-specific staining using the Chol/Trig Combo system (Helena Laboratories, Saitama, Japan). The liver and skeletal muscle tissue were homogenized in a mixture of chloroform and methanol (2:1 vol/vol), and the total lipid extracts were prepared according to the method of Folch et al. 16 The TG concentrations were measured, and tissue TG content (milligram per gram of tissue weight) was calculated.
Histopathologic Studies
Six rat retroperitoneal adipose tissues were collected from each group for histologic studies and fixed in 10% formalin solution. Paraffin-embedded sections were stained with hematoxylin and eosin (H&E) and impregnated with silver, and the area for a total of 434 adipocytes drawn from each rat (2600 adipocytes from 6 rats per group) was measured by using an imaging analysis system. Frequency distributions were created for all groups, and statistical analysis was performed on ratios of small-to-large adipocytes, as well as on mean adipocyte areas in all groups, with the adipocytes in the less than 25 percentile in size in group C defined as small adipocytes, and those in the more than 75 percentile in size in group C defined as large adipocytes.
Statistical Analysis
All numerical values were expressed as mean Ϯ SD. We applied one-way analysis of variance (ANOVA), and followed up with Scheffe's method as a post hoc test for any significant differences among the groups (P Ͻ .05). The level of P Ͻ .05 was considered to indicate statistical significance. The 2 test was used to test for any significant differences in the numbers of small adipocytes and large adipocytes between the four groups.
Results
No significant differences were seen in food intake between the groups. Although there were no significant differences in body weight between the groups, the telmisartan group showed a trend for decreased body weight compared to the other groups (control group, 583 Ϯ 39 g; amlodipine group, 557 Ϯ 32 g; valsartan group, 554 Ϯ 55 g; and telmisartan group, 539 Ϯ 18 g; all data obtained at the end of the study) (Fig. 1) . All animals in the amlodipine, valsartan, and telmisartan groups showed significantly lower systolic BP than that in the control group at the age of 22 weeks, although there were no significant differences between the amlodipine, valsartan, and telmisartan groups (Table 1) .
Although no significant differences were observed in the fasting plasma glucose level between the groups, the fasting plasma insulin level was significantly lower for the telmisartan group and tended to be lower for the valsartan group than the control group (Table 1 ). Moreover, the TG level before, 60, and 120 min after fat loading was significantly lower in the telmisartan group than that in the control group. Again, the TG level 60, 120, and 180 min after fat loading was also significantly lower for the telmisartan group than that in the valsartan group. The FFA level 60, 120, and 180 min after fat loading was significantly lower for the telmisartan group than that in the control group or in the amlodipine group, and the FFA level 120 min after fat loading was also lower for the telmisartan group than that for the valsartan group.
In the lipoprotein fraction analysis, the telmisartan group showed significantly lower very low-density lipoprotein (VLDL) levels than the control group, whereas there was no significant difference in chylomicron TG levels between the groups (Table 1) .
Subcutaneous, retroperitoneal, mesenteric, and epididymal adipose tissue weights, liver weights, and TG content in the skeletal muscle and liver tended to be lower for the telmisartan group than for the other groups, although there were no significant differences between the groups.
Histopathologic examination showed that small adipocytes in the adipose tissue were particularly abundant in the telmisartan group (Figs. 2 and 3C ). The average area of adipocytes was significantly smaller in the valsartan and telmisartan groups than in the control group or in the amlodipine group, whereas it was also significantly smaller in the telmisartan group than in the valsartan group ( Table 2 ). Frequency distribution tables showed that adipocyte areas in the valsartan and telmisartan groups shifted downward compared with that in the control group (Fig. 3B,C) , although almost the same distribution was observed in the amlodipine group (Fig. 3A) . The adipocyte area peaked between 6000 and 8000 m 2 in the control group and between 4000 and 6000 m 2 in the telmisartan group (Fig. 3C) . The numbers of small adipocytes in the valsartan and telmisartan groups were significantly higher than that in the control group, with the number of large adipocytes shown to be significantly lower in the valsartan and telmisartan groups than in the control group. Furthermore, the telmisartan group was shown to have a significantly higher number of small adipocytes, and a significantly lower number of large adipocytes compared to the valsartan group (Table 3) .
Discussion
In this experiment, the fasting plasma insulin level in the telmisartan group was significantly lower than that in the control group, which was assumed to indicate that telmisartan improved insulin resistance in these rats. 17 Beneficial effects of telmisartan on insulin resistance have been reported in animal experiments 9 and clinical studies, 18 -20 and our current results appear to support these published reports. Also, in the telmisartan group, the TG levels after the oral fat-loading test were significantly lower, accompanied by predominant decreases in VLDL (ie, TG-rich lipoprotein derived from the liver), thus indicating the over-riding effect of telmisartan on TG production in the liver, from that on the metabolism of TG-rich lipoprotein by lipoprotein lipase (LPL). Evaluation of adipose tissue cellularity revealed that telmisartan increased the number of small adipocytes, as well as decreased the number of large adipocytes, suggesting that the downsizing of adipocytes by telmisartan led to a decrease in the amount of FFA released from the adipocytes on lipolysis and that FFA entering the liver was reduced and the TG synthesis in the liver decreased, thereby accounting for the predominant decrease in VLDL.
With regard to the effects of ARBs on lipid metabolism, Okada et al 21 reported results showing the beneficial effects of olmesartan on insulin resistance and TG overproduction in the liver in fructose-fed rats, and their results appeared to be consistent with our current study results.
One possible mechanism by which ARBs exert their beneficial effects on insulin resistance is their potential to alter adipocyte size. For one, although Ang II is known to inhibit the differentiation of adipocytes and increase large adipocytes, 6, 7 olmesartan has been reported to downsize adipocytes and improve insulin resistance in fructose-fed rats. 8 It is thus likely that any ARB, with AT1 receptor antagonism, can counteract the effect of Ang II that inhibits the intracellular insulin-signaling pathway or increases oxidative stress, and at the same time promoting the differentiation and mobilization of preadipocytes to increase the number of small, insulin-sensitive adipocytes, and thus improve insulin resistance. In our experiment as well, significant downsizing of adipocytes was shown in the valsartan group as compared to the control or the amlodipine group, and the ARB-induced downsizing of adipocytes was considered to be associated with AT1 receptor antagonism as a class effect of ARBs. It was also reported that mice lacking Ang II type 1a receptor (Agtr1a) exhibited an attenuation of diet-induced weight gain and adiposity through increased energy expenditure. 22 Because plasma Ang II concentrations are elevated in Agtr1a Ϫ/Ϫ mice compared with Agtr1a ϩ/ϩ mice, 23 it is possible that the effect of Ang II by Agtr1b and Agtr2 contributes to the metabolic phenotypes of Agtr1a Ϫ/Ϫ mice. These observations, taken together, suggest that Agtr2 is important for the regulation of energy homeostasis and may be responsible for the attenuated adiposity in the telmisartan-and valsartan-treated rats as compared to amlodipine-treated rats in our study.
On the other hand, of the ARBs, telmisartan has been suggested to not have only AT1 receptor antagonism but also the PPAR-␥-mediated ability to improve insulin resistance. This PPAR-␥-mediated effect unique to telmisartan can be explained by its chemical structure properties as well as by its lipid solubility. 9 The PPAR-␥ is a transcription factor expressed in adipocytes, 24 and it has been suggested that as PPAR-␥ activity is increased, adipocytes become more differentiated and activated, and the ability of the adipose tissue to accumulate fat is increased, and the secretion of tumor necrosis factor-␣ (TNF-␣) and resistin is suppressed, whereas adiponectin production is promoted, 25, 26 leading to the improvement of insulin resistance. It was thus concluded that telmisartan caused downsizing of adipocytes, not only by its AT1 receptor antagonism, but also through its selective PPAR-␥ activation. Of note, recently, Sugimoto et al 11 reported that telmisartan suppresses increases in body weight in high fat diet-fed rats by increasing energy expenditure in these animals. Furthermore, another recent study 27 also suggests that telmisartan increases the expression of uncoupling protein 1 in the brown adipose tissue of diet-induced obese mice. The present study using OLETF rats also demonstrated that although there were no significant differences in food intake between the groups, the telmisartan-treated rats showed a trend for decreased body weight, decreased adipose tissue weight, and decreased TG tissue content compared to the other groups, a finding suggesting, consistent with the report of Sugimoto et al, 11 that telmisartan likely suppressed fat accumulation by increasing energy expenditure in the OLETF rats.
Although both valsartan and telmisartan downsized adipocytes, adipocyte downsizing was significantly greater with telmisartan compared to valsartan. The likely mechanism for this difference was thought to be the PPAR-␥-mediated action of telmisartan. * P Ͼ .05, ** P Ͻ .001 v control; † † P Ͻ .001 v amlodipine; § P Ͻ .01 v valsartan. Rats were treated with amlodipine (2 mg/kg), valsartan (10 mg/kg), or telmisartan (5 mg/kg) for 16 weeks.
